Cowen reaffirmed their hold rating on shares of Axovant Gene Therapies (NASDAQ:AXGT) in a research note issued to investors on Tuesday, AnalystRatings.com reports.

Several other equities research analysts also recently commented on the stock. Chardan Capital upgraded shares of Axovant Gene Therapies from a neutral rating to a buy rating and set a $32.00 target price on the stock in a research report on Monday, March 11th. Zacks Investment Research downgraded shares of First Bancorp from a buy rating to a hold rating in a research report on Friday, June 14th. JMP Securities lifted their target price on shares of Axovant Gene Therapies from $8.00 to $28.00 and gave the stock an outperform rating in a research report on Thursday, June 6th. HC Wainwright restated a buy rating and set a $25.00 price target on shares of Kadmon in a report on Tuesday, March 12th. Finally, ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $28.76.

NASDAQ:AXGT opened at $7.38 on Tuesday. The stock’s 50 day simple moving average is $6.16. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.41. Axovant Gene Therapies has a one year low of $3.81 and a one year high of $21.92. The firm has a market cap of $168.12 million, a P/E ratio of -0.92 and a beta of 1.28.

Axovant Gene Therapies (NASDAQ:AXGT) last posted its earnings results on Tuesday, June 11th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($1.70) by $1.25. On average, equities analysts predict that Axovant Gene Therapies will post -5.71 earnings per share for the current fiscal year.

In other news, CEO Pavan Cheruvu purchased 7,500 shares of the stock in a transaction on Friday, June 14th. The stock was purchased at an average price of $5.21 per share, for a total transaction of $39,075.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.20% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in AXGT. Marshall Wace LLP bought a new position in Axovant Gene Therapies during the 1st quarter worth approximately $272,000. Primecap Management Co. CA bought a new position in Axovant Gene Therapies during the 1st quarter worth approximately $1,400,000. Finally, Sphera Funds Management LTD. bought a new position in Axovant Gene Therapies during the 1st quarter worth approximately $6,794,000.

About Axovant Gene Therapies

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Read More: Why is Cost of Capital Important?

Analyst Recommendations for Axovant Gene Therapies (NASDAQ:AXGT)

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.